365
0 Kommentare
Horizon Pharma plc Prices Offering of $350 Million of 2.50% Exchangeable Senior Notes - Seite 3
Forward-Looking Statements
This press release includes forward-looking statements regarding Horizon's financing plans, including statements related to Horizon's offering of the notes, the terms of the notes and the intended use of net proceeds of the offering. Such statements are subject to certain risks and uncertainties including, without limitation, risks related to whether Horizon will consummate the offering of the notes on the expected terms, or at all, market and other general economic conditions, whether Horizon will be able to satisfy the conditions required to close any sale of the notes, and the fact that Horizon's management will have broad discretion in the use of the proceeds from any sale of the notes. Horizon's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Horizon's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Horizon. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Horizon are described in additional detail in Horizon Pharma plc's annual report on Form 10-K for the year ended December 31, 2014, which is on file with the Securities and Exchange Commission.
Lesen Sie auch
Contacts:
Investors:
Robert F. Carey
Executive Vice President, Chief Business Officer
Email Contact
U.S. Media Contact:
Geoff Curtis
Email Contact
+1 312 233-1253
Ireland Media Contact:
Ray Gordon
Gordon MRM
Email Contact
+353 (87) 2417373